Explore the latest news from Khondrion and its team.
December 4, 2015 - FOR IMMEDIATE RELEASE Khondrion reports successful outcome of KH176 Phase 1 Clinical trials NIJMEGEN – Khondrion, the...
Khondrion has received an Orphan Drug Designation from the European Commission of its frontrunner compound...
Khondrion receives Orphan Drug Designation for treatment of MELAS syndrome NIJMEGEN – Khondrion, the Dutch pharmaceutical company focusing on small...
NIJMEGEN – Khondrion, the Dutch biopharmaceutical company focusing on small molecule therapeutics for mitochondrial...
Former Kinesis Director Clinical Development Edwin Spaans appointed as Khondrion's Chief Medical Officer. NIJMEGEN –December 15, 2014 ‐ Khondrion,...
Published: 25 November 2014 Khondrion has received an Orphan Drug Designation from the FDA of its frontrunner compound KH176, in the treatment of...
We recently sat down with Kasey Woleben, Co-founder, and Sophia Zilber, Board Member and Patient Registry Director of Cure Mito Foundation, to talk...
As 2021 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the past year and the continued progress Khondrion has made in its development of...
Movement, the act or process of moving, the change of place or position or posture, is a complex process under the control of many different parts...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? Jan Smeitink and I have been colleagues since the...
How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? I first heard about Khondrion from CEO Jan...
Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...
